2023-09-15 17:37:08 ET
More on Novartis
- Seeking Alpha’s Quant Rating on Novartis
- Historical earnings data for Novartis
- Dividend scorecard for Novartis
- Financial information for Novartis
- Novartis: Q2 Beats Expectations, But Still Pricey
- Novartis: Strong Growth And Continued Expansion For KISQALI
- Novartis AG ( NVS ) Q2 2023 Earnings Call Transcript
- EMA advisors recommend many new meds at latest meeting
- Sandoz to commercialize biosimilar to J&J blockbuster drug Stelara
- AbbVie immunology chief to lead Novartis commercial operations
- Novartis ending development of pancreatic cancer asset licensed from XOMA
For further details see:
Novartis shareholders approve 100% spinout of Sandoz unit